Талерт
Основна информация
- Търговско наименование:
- Талерт 1 mg/ml сироп - 120 ml x 1
- Активна съставка:
- Цетиризина дихидрохлорид
- Предлага се от:
- СОФАРМА АД
- АТС код:
- R06AE7
- INN (Международно Name):
- Cetirizine dihydrochloride
- Използвай за:
- Хората
- Вид на лекарството:
- алопатични наркотици
Документи
- за широката общественост:
- Листовка за пациента
-
- за медицински специалисти:
- кратка характеристика на продукта
-
Локализация
- Предлага се в:
-
България
- Език:
- български
Терапевтична информация
- Каталог на резюме:
- Talert, 1 mg/ml syrup - 120 ml x 1
Друга информация
Състояние
- Източник:
- Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
- Номер на разрешението:
- 20080291
- Дата Оторизация:
- 25-06-2014
- Последна актуализация:
- 01-06-2018
Листовка за пациента
- Достъпът до този документ е достъпен само за регистрирани потребители.
Регистрирайте се сега за пълен достъп
21-8-2018
Orphan designation: R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, for the: Treatment of hereditary angioedema
Europe - EMA - European Medicines Agency
1-8-2018
Human medicines European public assessment report (EPAR): Ceplene, histamine dihydrochloride, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
14-6-2018
Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, for the: Treatment of primary myelofibrosis
Europe - EMA - European Medicines Agency
14-6-2018
Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, for the: Treatment of post-essential thrombocythaemia myelofibrosis
Europe - EMA - European Medicines Agency
14-6-2018
Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, for the: Treatment of post-polycythaemia vera myelofibrosis
Europe - EMA - European Medicines Agency
13-6-2018
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of post-essential thrombocythaemia myelofibrosis
Europe - EMA - European Medicines Agency
13-6-2018
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of primary myelofibrosis
Europe - EMA - European Medicines Agency
13-6-2018
Orphan designation: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate, for the: Treatment of post-polycythaemia vera myelofibrosis
Europe - EMA - European Medicines Agency
30-7-2018
Ceplene (Noventia Pharma Srl)
Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36
Europe -DG Health and Food Safety
29-6-2018
EU/3/18/2028 (BioCryst UK Ltd)
EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18
Europe -DG Health and Food Safety
14-6-2018
Kuvan (BioMarin International Limited)
Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018
Europe -DG Health and Food Safety
12-6-2018
EU/3/10/811 (Celgene Europe B.V.)
EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03
Europe -DG Health and Food Safety
12-6-2018
EU/3/10/810 (Celgene Europe B.V.)
EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03
Europe -DG Health and Food Safety
12-6-2018
EU/3/10/794 (Celgene Europe B.V.)
EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03
Europe -DG Health and Food Safety
12-6-2018
EU/3/11/888 (Gilead Sciences Ireland UC)
EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03
Europe -DG Health and Food Safety
12-6-2018
EU/3/11/887 (Gilead Sciences Ireland UC)
EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03
Europe -DG Health and Food Safety
12-6-2018
EU/3/11/886 (Gilead Sciences Ireland UC)
EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03
Europe -DG Health and Food Safety